Combined hERG channel inhibition and disruption of trafficking in drug-induced long QT syndrome by fluoxetine: A case-study in cardiac safety pharmacology

British Journal of Pharmacology

Volumn 149, Issue 5, 2006, Pages 457-459

  Hancox, J C ^a   Mitcheson, J S ^b  

^a SCHOOL OF MEDICAL SCIENCES   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Arrhythmia; Fluoxetine; hERG; Human ether go go related gene; Long QT syndrome; Norfluoxetine; Potassium channel; Prozac; QT interval; Safety pharmacology

Indexed keywords

DRUG METABOLITE; FLUOXETINE; NORFLUOXETINE; POTASSIUM CHANNEL HERG; RECOMBINANT PROTEIN;

CELL MEMBRANE; DRUG BINDING; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG INHIBITION; DRUG MECHANISM; HUMAN; HUMAN CELL; LONG QT SYNDROME; MUTATIONAL ANALYSIS; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; REVIEW;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ETHER-A-GO-GO POTASSIUM CHANNELS; FEMALE; FLUOXETINE; HUMANS; LONG QT SYNDROME; MALE; OVERDOSE; PROTEIN TRANSPORT;

EID: 33750435523     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706890     Document Type: Review

References (22)

1. Cordes JS, Sun Z, Lloyd DB, Bradley JA, Opsahl AC, Tengowski MW et al. (2005). Pentamidine reduces hERG expression to prolong the QT interval. Br J Pharmacol 145: 15-23.
2. Delisle BP, Anson BD, Rajamani S, January CT (2004). Biology of cardiac arrhythmias: ion channel protein trafficking. Circ Res 94: 1418-1428.
3. Dubnov G, Fogelman R, Merlob P (2005). Prolonged QT interval in an infant of a fluoxetine treated mother. Arch Dis Child 90: 972-973.
4. Ficker E, Kuryshev YA, Dennis AT, Obejero-Paz C, Wang L, Hawryluk P et al. (2004). Mechanisms of arsenic-induced prolongation of cardiac repolarization. Mol Pharmacol 66: 33-44.
5. Hoffmann P, Warner B (2006). Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? a review of emerging trends. J Pharmacol Toxicol Methods 53: 87-105.
6. Isbister GK, Bowe SJ, Dawson A, Whyte IM (2004). Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol 42: 277-285.
7. Kamiya K, Niwa R, Mitcheson JS, Sanguinetti MC (2006). Molecular determinants of HERG channel block. Mol Pharmacol 69: 1709-1716.
8. Kuryshev YA, Ficker E, Wang L, Hawryluk P, Dennis AT, Wible BA et al. (2005). Pentamidine induced long QT syndrome and block of hERG trafficking. J Pharmacol Exp Ther 312: 316-323.
9. Magyar J, Szentandrassy N, Banyasz T, Kecskemeti V, Nanasi PP (2004). Effects of norfluoxetine on the action potential and transmembrane ion currents in canine ventricular cardiomyocytes. Naunyn Schmiedebergs Arch Pharmacol 370: 203-210.
10. Milnes JT, Crociani O, Arcangeli A, Hancox JC, Witchel HJ (2003). Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652. Br J Pharmacol 139: 887-898.
11. Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG (2005). QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine. Ann Pharmacother 39: 543-546.
12. Pacher P, Magyar J, Szigligeti P, Banyasz T, Pankucsi C, Korom Z et al. (2000). Electrophysiological effects of fluoxetine in mammalian cardiac tissues. Naunyn Schmiedebergs Arch Pharmacol 361: 67-73.
13. + channel block and disruption of protein trafficking by fluoxetine and norfluoxetine. Br J Pharmacol 149: 481-489 (this issue).
14. + channel blockade: current knowledge and strategies for the early prediction during drug development. Med Res Rev 25: 133-166.
15. Sanguinetti MC, Mitcheson JS (2005). Predicting drug-hERG channel interactions that cause acquired long QT syndrome. Trends Pharmacol Sci 26: 119-124.
16. Sanguinetti MC, Tristani-Firouzi M (2006). hERG potassium channels and cardiac arrhythmia. Nature 440: 463-469.
17. Thomas D, Gut B, Wendt-Nordahl G, Kiehn J (2002). The antidepressant drug fluoxetine is an inhibitor of human ether-à-go-go-related gene (HERG) potassium channels. J Pharmacol Exp Ther 300: 543-548.
18. Wible BA, Hawryluk P, Ficker E, Kuryshev YA, Kirsch G, Brown AM. (2005). HERG-Lite®: a novel comprehensive high-throughput screen for drug-induced hERG risk. J Pharmacol Toxicol Methods 52: 136-145.
19. Wilting I, Smals OM, Holwerda NJ, Meyboom RH, de Bruin ML, Egberts TC (2006). QTc prolongation and torsades de pointes in an elderly woman taking fluoxetine. Am J Psychiatry 163: 325.
20. Witchel HJ, Hancox JC (2000). Familial and acquired long QT syndrome and the cardiac rapid delayed rectifier potassium current. Clin Exp Pharmacol Physiol 27: 753-766.
21. Witchel HJ, Pabbathi VK, Hofmann G, Paul AA, Hancox JC (2002). Inhibitory actions of the selective serotonin re-uptake inhibitor citalopram on HERG and ventricular L-type calcium currents. FEBS Lett 512: 59-66.
22. Yap YG, Camm AJ (2003). Drug induced QT prolongation and torsades de pointes. Heart 89: 1363-1372.